# Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.

> **NCT05681273** · PHASE1 · COMPLETED · sponsor: **Chipscreen Biosciences, Ltd.** · enrollment: 48 (actual)

## Conditions studied

- T2DM

## Interventions

- **DRUG:** Chiglitazar
- **DRUG:** Empagliflozin
- **DRUG:** Atorvastatin
- **DRUG:** Valsartan

## Key facts

- **NCT ID:** NCT05681273
- **Lead sponsor:** Chipscreen Biosciences, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-17
- **Primary completion:** 2023-03-21
- **Final completion:** 2023-03-21
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2023-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05681273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05681273, "Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05681273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*